Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT01309204

Open-Angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

NCT00348400

Glaucoma

COMPLETED PHASE4

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00314158

Open-angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

NCT01297920

Open-Angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH

NCT01721707

Open Angle Glaucoma Ocular Hypertension

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

latanoprost 0.005% eye drops and brimonidine 0.1% eye drops

Intervention Type DRUG

latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months

2

Group Type ACTIVE_COMPARATOR

latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

Intervention Type DRUG

latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

latanoprost 0.005% eye drops and brimonidine 0.1% eye drops

latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months

Intervention Type DRUG

latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xalatan® Alphagan® P Xalatan® Azopt®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Glaucoma or ocular hypertension in both eyes
* Currently being treated with latanoprost 0.005% QD
* IOP greater than or equal to 18mm Hg on latanoprost 0.005%
* Best-corrected VA of 20/200 or better in each eye
* Visual field within 6 months of study entry